TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02388529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTP-131
Description: MTP-131 (low dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTP-131
Description: MTP-131 (intermediate dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTP-131
Description: MTP-131 (high dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator (at each dose cohort) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
Study: NCT02187094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-6499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-6499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-6499

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01294735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-4827
Description: MK-4827 in combination with temozolomide utilizing a number of doses and schedules for both drugs will be explored to determine a preliminary MTD. The preliminary MTD will then be confirmed in participants with melanoma and glioblastoma multiforme.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-4827
Description: MK-4827 in combination with temozolomide utilizing a number of doses and schedules for both drugs will be explored to determine a preliminary MTD. The preliminary MTD will then be confirmed in participants with melanoma and glioblastoma multiforme.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-4827
Description: MK-4827 in combination with temozolomide utilizing a number of doses and schedules for both drugs will be explored to determine a preliminary MTD. The preliminary MTD will then be confirmed in participants with melanoma and glioblastoma multiforme.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: MK-4827 in combination with temozolomide utilizing a number of doses and schedules for both drugs will be explored to determine a preliminary MTD. The preliminary MTD will then be confirmed in participants with melanoma and glioblastoma multiforme.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: MK-4827 in combination with temozolomide utilizing a number of doses and schedules for both drugs will be explored to determine a preliminary MTD. The preliminary MTD will then be confirmed in participants with melanoma and glioblastoma multiforme.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: MK-4827 in combination with temozolomide utilizing a number of doses and schedules for both drugs will be explored to determine a preliminary MTD. The preliminary MTD will then be confirmed in participants with melanoma and glioblastoma multiforme.
Study: NCT01102153

Intervention type: DEVICE
Intervention: Coolgard
Description: invasive cooling via femoral ICY-catheter

Intervention type: DEVICE
Intervention: ArcticSun
Description: non-invasive surface cooling by saline-cooled thermo-vest
Study: NCT02560688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1040b
Description: 20 mg single 12-hour intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1040b
Description: 20 mg single 12-hour intravenous infusion

Intervention type: DRUG
Group type: OTHER
Intervention: Clopidogrel
Description: Clopidogrel (Plavix) administered orally 300 mg loading dose on Day 1 followed by 75 mg daily on Days 2-5
Study: NCT03636022

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR System
Description: Use of virtual reality to deliver exposure therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Use of conventional delivery of exposure therapy
Study: NCT02814305

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational
Description: Patient watches a video featuring narrative vignettes of patients who developed opioid dependence or abuse after using opioids postoperatively
Study: NCT05640596

Intervention type: DRUG
Intervention: Betamethasone
Study: NCT02560688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel (Plavix) administered orally 300 mg loading dose on Day 1 followed by 75 mg daily on Days 2-5
Study: NCT00851942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synacthen (Tetracosactrin)
Description: IV injection of 250 micrograms of Synacthen in 1ml
Study: NCT01492387

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discontinuation of antibiotic therapy
Description: Patients randomized in the Individualized Arm will be treated according to clinical response: antibiotic therapy will be discontinued 48 hours after the day that the patient reaches clinical stability, with at least 5 days of total antibiotic treatment.
Study: NCT01833832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Patients who are successfully debulked will then undergo hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery
Description: Patients will undergo cytoreductive surgery to achieve a Completeness of Cytoreduction Score (CC) of 0 or 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium thiosulfate
Description: sodium thiosulfate will be given to limit the toxicity of cisplatin
Study: NCT03517358

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Service of care
Description: Subjects will be receiving care from case management or clinical pharmacy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Service of care
Description: Subjects will be receiving care from case management or clinical pharmacy.
Study: NCT00642759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given by infusion on day 1 of each 3 week cycle for a maximum of 6 cycles
Study: NCT00479141

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV skills training
Description: Eight 2-hour group skills training sessions will occur during Weeks 1 through 8 and booster sessions will occur every two months during Months 3 through 15

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Popular Opinion Leaders training
Description: Two-hour training sessions about anti-stigma and anti-discrimination will occur for 4 weeks, followed by support meetings every 2 months during Months 2 through 13.
Study: NCT02057718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM001 (Maralixibat)
Description: LUM001 also known as Maralixibat (MRX) oral dose up to twice a day (BID).
Study: NCT02578212

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo
Study: NCT00197015

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix®
Description: 2 doses administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix®
Description: 2 doses administered intramuscularly

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix®
Description: 2 doses administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M-M-R®II
Description: 1 dose administered subcutaneously

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: M-M-R®II
Description: 1 dose administered subcutaneously
Study: NCT01599754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Axitinib 5 mg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice daily
Study: NCT02938065

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasound
Description: Baseline ultrasound is performed upon arrival. Ultrasound is performed when beverage is consumed and then every 30 minutes thereafter until stomach is empty.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasound
Description: Baseline ultrasound is performed upon arrival. Ultrasound is performed when beverage is consumed and then every 30 minutes thereafter until stomach is empty.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasound
Description: Baseline ultrasound is performed upon arrival. Ultrasound is performed when beverage is consumed and then every 30 minutes thereafter until stomach is empty.

Intervention type: OTHER
Group type: OTHER
Intervention: 2% milk
Description: 16 participants will drink 10 ounces of 2% milk

Intervention type: OTHER
Group type: OTHER
Intervention: apple juice
Description: 16 participants will drink 10 ounces of apple juice

Intervention type: OTHER
Group type: OTHER
Intervention: ensure clear
Description: 16 participants will drink 10 ounces of ensure clear
Study: NCT02924506

Intervention type: DEVICE
Group type: OTHER
Intervention: Mobi-C prothesis
Description: Mobi-C Prothesis, LDR Medical (company)

Intervention type: DEVICE
Group type: OTHER
Intervention: ProDisc-C prothesis
Description: ProDisc-C prothesis, Vivo Depuy Synthes (company)
Study: NCT01350037

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alfentanil
Description: Alfentanil is a potent but short-acting synthetic opioid analgesic drug, used for anaesthesia in surgery. It is an analogue of fentanyl with around 1/10 the potency of fentanyl and around 1/3 of the duration of action, but with an onset of effects 4x faster than fentanyl.It is an OP3 mu-agonist.Alfentanil is administered by the parenteral (injected) route for fast onset of effects and precise control of dosage.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alfentanil
Description: Alfentanil is a potent but short-acting synthetic opioid analgesic drug, used for anaesthesia in surgery. It is an analogue of fentanyl with around 1/10 the potency of fentanyl and around 1/3 of the duration of action, but with an onset of effects 4x faster than fentanyl.It is an OP3 mu-agonist.Alfentanil is administered by the parenteral (injected) route for fast onset of effects and precise control of dosage.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanil
Description: Remifentanil is a potent ultra short-acting synthetic opioid analgesic drug. It is given to patients during surgery to relieve pain and as an adjunct to an anaesthetic. Remifentanil is used for sedation as well as combined with other medications for use in general anesthesia. The use of remifentanil has made possible the use of high dose opioid and low dose hypnotic anesthesia, due to synergism between remifentanil and various hypnotic drugs and volatile anesthetics.It is administered in the form remifentanil hydrochloride and in adults is given as an intravenous infusion in doses ranging from 0.1 microgram per kilogram per minute to 0.5 (µg/kg)/min.
Study: NCT03152136

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Cala ONE device
Description: The Cala ONE device is a wrist-worn stimulator which applies a tremor-customized stimulation pattern to an individual's nerves.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cala ONE device
Description: The Cala ONE device is a wrist-worn stimulator which applies a tremor-customized stimulation pattern to an individual's nerves.
Study: NCT02882399

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shortystrap
Study: NCT00660868

Intervention type: DRUG
Intervention: Pentoxifylline retard 400mg
Description: Agapurin retard 400mg 3/day per os for 3 weeks
Study: NCT03577886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-6114
Description: CDX-6114 will be administered as a single, oral dose solution at dose levels of 0.225, 0.75, 2.25, and 7.5 g.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate Buffer Diluent oral solution
Study: NCT01774630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: 300 mg/twice a day
Study: NCT04139031

Intervention type: DEVICE
Intervention: Ultrasonographic measurement of corrected flow time in carotid artery
Description: Corrected carotid artery flow time is measured using 6-13 MHz linear probe on a portable ultrasound machine. On the two-dimensional image, the optimal image of the long-axis view is obtained at the left common carotid artery. The sample volume is placed on the center of the lumen, 2 cm proximal to the bulb, and a pulsed wave Doppler examination was performed while the Doppler beams were adjusted to ensure \< 60° of angle for the best signal. Then, cardiac cycle time and carotid flow time is measured. Carotid flow time is measured between the upstroke of the flow tracing and the dicrotic notch, and it is corrected for pulse rate by dividing flow time by the square root of the cardiac cycle time to calculate corrected carotid artery flow time (flow time/√cycle time).
Study: NCT00642759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given by infusion once weekly (days 1, 8 and 15) of each three week cycle for a maximum of 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV infusion
Study: NCT04614337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM-201
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM-201
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM-201
Description: Administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhGH Norditropin® pen (34 µg/kg)
Description: Administered subcutaneously (s.c., under the skin) once daily.
Study: NCT04139408

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Disposable Pulmonary Surgical Marker
Description: The subjects will undergo Marker placement procedure, within 24h before VATS.
Study: NCT00561379

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHOP+RITUXIMAB
Description: CHOP-14- Rituximab x 8 courses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CEEP-RITUXIMAB
Description: High dose chemotherapy with rituximab including autologous stem cell support.
Study: NCT01064726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 800 mg oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Description: 200 mcg intra-nasal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00726583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PX-866
Description: Oral solution, dose escalation, once per day on days 1 to 5 and 8 to 12 or days 1-28 of a 28 day cycle, until progression or development of unacceptable toxicity
Study: NCT01174563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib [Tarceva]
Description: 150 mg orally daily, with dose-reductions to 100 mg or 50 mg orally daily according to protocol
Study: NCT05671666

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Urea cycle flux study
Description: Quantification of ureagenesis
Study: NCT03100279

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping Cat/CAT Project
Description: The Coping Cat program, developed by Kendall and colleagues (Kendall, 1994; Kendall, 2000; Kendall, Kane, Howard, \& Siqueland, 1989; Kendall, Flannery-Schroeder et al., 1997), involves (1) teaching children to identify their own anxious feelings and physiological signs of anxiety, (2) teaching children to identify their own anxiety-provoking cognitions, (3) developing a plan to guide coping - a plan that involves changing the child's thoughts (into positive self-talk) and actions (into self-initiated exposures), and (4) self-evaluation and self-reward. The therapist uses modeling (e.g., revealing therapist's own anxiety and sharing successful coping experiences), in vivo exposure tasks, role-playing (e.g., to prepare for exposure tasks), relaxation training, and contingent reinforcement (e.g., for trying and for succeeding at exposure tasks), in developing these four themes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary and Secondary Coping Enhancement Therapy
Description: PASCET is a brief (11-15 sessions) CBT program for depressed youths typically aged 8-15. Sessions and practice assignments are built on findings concerning cognitive and behavioral features of youth depression (e.g., Lewinsohn et al., 1990; Stark et al., 1987), and on the two-process model of perceived control and coping (Rothbaum, Weisz, \& Snyder, 1982; Weisz et al., 1984a,b). In this model, primary control involves efforts to cope by making objective conditions (e.g., one's activities, one's peer status) conform to one's wishes. In contrast, secondary control involves coping by adjusting oneself (e.g., one's expectations, interpretations) to fit objective conditions, so as to influence their subjective impact without altering the actual conditions. The goal is for youngsters to build their skills in primary and secondary control coping, and apply those skills to events and conditions that can trigger depression. Therapists are guided by a Therapist's Manual and use a youth workbook.
Study: NCT02124408

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Behavioral Intervention
Study: NCT01508767

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Removal of urethral catheter
Description: All participants are to have a urethral catheter placed following successful placement of an epidural catheter for analgesia prior to undergoing colorectal resection. Following urethral catheter placement participants will be randomly assigned to either the experimental arm or the control arm. Participants assigned to the experimental arm will have their urethral catheters removed at 48 hours following surgery. Participants assigned to the control group will have their urethral catheters removed within 12 hours of withdrawal of the epidural infusion, as is standard practice in our institution.

Intervention type: OTHER
Group type: OTHER
Intervention: Removal of urethral catheter
Description: All participants are to have a urethral catheter placed following successful placement of an epidural catheter for analgesia prior to undergoing colorectal resection. Following urethral catheter placement participants will be randomly assigned to either the experimental arm or the control arm. Participants assigned to the experimental arm will have their urethral catheters removed at 48 hours following surgery. Participants assigned to the control group will have their urethral catheters removed within 12 hours of withdrawal of the epidural infusion, as is standard practice in our institution.
Study: NCT02038036

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Available Therapy
Description: Best Available Therapy as selected by the investigator from: Hydroxyurea, Pegylated-Interferon (IFN/PEG-IFN), pipobroman, anagrelide, IMIDs, or observation. Participants randomized to BAT who did not respond by Week 28 were eligible to crossover and start treatment with ruxolitinib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib was administered at a starting dose of 10 mg twice a day (bid). Dose was adjusted based on efficacy and safety parameters up to a maximum dose of 25 mg bid.
Study: NCT02946697

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social support intervention
Description: The social support intervention is a 7-week program includes educational and peer mentoring support components. The education curriculum provides information on recognizing side effects of treatment and differentiating them from symptoms of cancer recurrence, physical therapy and alternative treatment, stress management, recognizing depression and managing emotional problems, communication with family members, and body image. The peer-support component assigns each participant with a mentor who is a breast cancer survivor. They share their own experience with participants and also make weekly phone calls to mentees during the intervention to provide support and address remaining concerns.
Study: NCT04174586

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: microtransplantation
Description: HLA mismatched donor cord blood infusion
Study: NCT04316143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral zamicastat
Description: Tablets for oral administration under fed conditions containing 100 mg of zamicastat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral zamicastat
Description: Tablets for oral administration under fed conditions containing 100 mg of zamicastat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral zamicastat
Description: Tablets for oral administration under fed conditions containing 100 mg of zamicastat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral zamicastat
Description: Tablets for oral administration under fed conditions containing 100 mg of zamicastat
Study: NCT04171960

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw
Description: Venous whole blood collection within 12 hours and 12-24 hours following injury.
Study: NCT00197015

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VARIVAX®
Description: 1 dose administered subcutaneously

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VARIVAX®
Description: 1 dose administered subcutaneously
Study: NCT00988286

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CEP, MEP, TMS
Description: Patients and healthy volunteers will undergo cortical evoked potentials (CEP), motor evoked potentials (MEP) and transcranial evoked potentials (TMS).
Study: NCT04171960

Intervention type: OTHER
Intervention: Outcome assessments
Description: Administered at baseline.
Study: NCT04628585

Intervention type: OTHER
Intervention: Safety and efficacy assessments
Description: Safety evaluations, disease-specific assessments, and assessments to monitor for long-term complications of autologous transplant
Study: NCT02298530

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination of caffeine and theanine
Description: Beverage containing caffeine and theanine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Caffeine
Description: Beverage containing caffeine
Study: NCT05491720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RisperiDONE 1 MG/ML
Description: Patients will receive two daily Risperidone 1 mg tablets (Sobhan Pharmaceutical Company) for 10 consecutive days
Study: NCT02215772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 44370 BS
Study: NCT01497119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39758979, 300 mg
Description: Type=exact number, unit=mg, number=300, form=tablet, route=oral use, once daily for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39758979, 100 mg
Description: Type=exact number, unit=mg, number=100, form=tablet, route=oral use, once daily for 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form=tablet, route=oral use, once daily for 6 weeks.